Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.61 USD -0.62%
Market Cap: 427.2m USD
Section:
 

Relative Value

The Relative Value of one AKBA stock under the Base Case scenario is 2.72 USD. Compared to the current market price of 1.61 USD, Akebia Therapeutics Inc is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AKBA Relative Value
Base Case
2.72 USD
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
33
vs Industry
72
Median 3Y
1.7
Median 5Y
1.7
Industry
7.9
Forward
1.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6
Median 5Y
-2.5
Industry
23.7
Forward
35.9
More Details
13.2
P/OCF
P/OCF
Price to OCF
13.2
vs History
3
vs Industry
Median 3Y
-7.2
Median 5Y
-2.9
Industry
22
More Details
10.2
P/FCFE
P/FCFE
Price to FCFE
10.2
vs History
7
vs Industry
Median 3Y
-2.7
Median 5Y
-2.2
Industry
23.8
More Details
10.3
P/B
P/B
Price to Book Value
10.3
vs History
17
vs Industry
2
Median 3Y
-6.2
Median 5Y
2
Industry
3.3
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
22
vs Industry
63
Median 3Y
1.6
Median 5Y
1.2
Industry
8.3
Forward
1.8
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
34
vs Industry
64
Median 3Y
2
Median 5Y
2
Industry
10.1
More Details
14.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.4
vs History
36
vs Industry
1
Median 3Y
22.4
Median 5Y
0.5
Industry
6.4
More Details
21.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
21.8
vs History
7
vs Industry
Median 3Y
-3.9
Median 5Y
-1.4
Industry
7
Forward
10.6
More Details
13.6
EV/OCF
EV/OCF
Enterprise Value to OCF
13.6
vs History
3
vs Industry
Median 3Y
-7.2
Median 5Y
-2.5
Industry
8.3
More Details
13.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13.7
vs History
3
vs Industry
Median 3Y
-7.1
Median 5Y
-2.5
Industry
6.5
More Details
2.3
EV/IC
EV/IC
Enterprise Value to IC
2.3
vs History
19
vs Industry
41
Median 3Y
1.7
Median 5Y
1.1
Industry
5.7
More Details

Multiples Across Competitors

AKBA Competitors Multiples
Akebia Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Akebia Therapeutics Inc
NASDAQ:AKBA
427m USD 1.9 -26.8 14.4 21.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 786 100.8 -160 580.3 -194 995.7 -192 770.6
US
Abbvie Inc
NYSE:ABBV
396.4B USD 6.6 168.8 16.4 23.2
US
Amgen Inc
NASDAQ:AMGN
175.4B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.2B USD 9.7 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 085.2 -532.1 -579.4 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84.2B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
45.1B EUR 14.7 34.5 59.6 61.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.7B USD 16.1 1 186.2 155.7 188.9
P/E Multiple
Earnings Growth PEG
US
Akebia Therapeutics Inc
NASDAQ:AKBA
Average P/E: 187.5
Negative Multiple: -26.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 580.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.5
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 186.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Akebia Therapeutics Inc
NASDAQ:AKBA
Average EV/EBITDA: 36.5
14.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 995.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
59.6
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.7
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Akebia Therapeutics Inc
NASDAQ:AKBA
Average EV/EBIT: 42.6
21.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 770.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
61.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.9
N/A N/A

See Also

Summary
AKBA intrinsic value, competitors valuation, and company profile.
DCF Valuation
AKBA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AKBA stock valuation using valuation multiples.
Wall Street Estimates
AKBA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AKBA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.